0
1. 4. 2017.
FIRST RESULTS OF A‐PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY: PNFLBA‐16